Drug intelligence / Profile preview

RLS-0088

Development stage: Preclinical
Lead developer: ReAlta Life Sciences
Modality: Peptides

Overview

RLS-0088 is a synthetic peptide drug candidate developed by ReAlta Life Sciences. It acts as an inhibitor of several key components in the complement and inflammatory pathways, specifically targeting Complement C1r, Complement C1s, Mannan-binding lectin serine proteases (MASPs), and Myeloperoxidase (MPO). The primary therapeutic area under investigation for RLS-0088 is hemic and lymphatic diseases, with a specific focus on blood platelet disorders. As of the latest available information, RLS-0088 remains in preclinical development[1][4].

Targets

C1R (Complement component 1r subcomponent)C1S (Complement component 1s subcomponent serine protease)MASP (MASP family)MPO (Myeloperoxidase)

Beyond the preview

Go deeper on RLS-0088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLS-0088.